Article Details

Bimekizumab Provides Sustained Psoriasis Benefit, Tolerability Over 3 Years - HCPLive

Retrieved on: 2022-10-23 20:03:05

Tags for this article:

Click the tags to see associated articles and topics

Bimekizumab Provides Sustained Psoriasis Benefit, Tolerability Over 3 Years - HCPLive. View article details on hiswai:

Excerpt

Investigators concluded the findings indicate a sustained and tolerable efficacy of bimekizumab in patients receiving long-term care for psoriasis ...

Article found on: www.hcplive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up